ReNeuron Group PLC (AIM: RENE) said it remained in negotiations with potential partners for all of its key programmes.
The stem cells specialist, which was providing an update on its progress ahead of its annual meeting on Tuesday, has two active clinical trials treating patients respectively for a blindness-causing disease called retinitis pigmentosa (RP) and stroke.
The former is a phase I/II open label study of its hRPC treatment, which has enjoyed some early success by improving the sight of RP sufferers.
ReNeuron said dosing for a third group of three patients is complete, with dosing on the remaining cohort underway. Results from the clinical assessment will be showcased at the American Academy of Ophthalmology in San Francisco from October 12.
These results will be integral to conversations with regulators in the US and Europe, ReNeuron said.
There was a minor setback for the US phase IIb placebo-controlled PISCES III trial of its potential stroke treatment involving 110 people.
“Due to the nature and complexity of the study, patient recruitment has been slower than anticipated and we are pursuing or evaluating a number of further initiatives to address this,” investors were told.
“These include potential amendments to the clinical trial protocol as well as various patient recruitment initiatives to better target eligible patients for the study.”
The aforementioned are expected to extend the term of PISCES III study by three to six months to first half of 2021, ReNeuron confirmed.
Shares in the company were up 1% to 202p on Tuesday morning.
-- Adds share price --